Drug Approval | August 17, 2021
Lupin receives tentative U.S. FDA approval for Brivaracetam tablets
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Demand normalisation post the second wave contributed to the steady growth
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
India business contributes to a stellar performance
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
Subscribe To Our Newsletter & Stay Updated
